Loading
EB-NK-301 is an experimental donor-derived immune-cell therapy aimed at TROP2. Its registered trial combines phase 1 and phase 2 testing; no clinical benefit is established.
EB-NK-301 is an allogeneic TROP2 CAR-NK product in NCT07589530, a recruiting phase 1/2 study. The registry plans 60 participants and marks the March 2, 2026 start as actual. Primary completion is estimated for February 14, 2027; the record was last updated May 15, 2026. No tabular results are posted. The combined phase 1/2 designation does not establish completed phase 2 efficacy or postoperative TNBC benefit.
CAR-NK cell therapy directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to TROP2.
1.EB-NK-301 slips into a pocket on TROP2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EB-NK-301" OR ABSTRACT:"EB-NK-301" OR TITLE:"TROP2-CAR NK" OR ABSTRACT:"TROP2-CAR NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EB-NK-301, not a curated reading list.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/